ET Now: Let’s talk about auto space because today all the eyes are on full auto sales numbers. So far, we have a lot of players and so far, the only thing we are now looking at is the M&M tractor segment and the estimates that are defeated are M&M Auto toe, Ashok Leyland, TVS Motors and Tata Motors CV. Therefore, so far there are a large number of mixed numbers as many of them are also in line. What do you take on auto sales numbers we have seen and how do they work against your expectations?
Sudip Bandyapadhyay: Well, that’s what I say it corresponds to the expectation, at least that’s what we were pencing. We were reasonably convinced that the number of commercial vehicles would be better and improvement in line and it shows the number of ASHOK Leyland. Even if you take a look at Eicher Motors, part of their professional vehicle shows promise and improvement. As far as domestic two-wheeler sales are concerned, apparently, it has been subdued. See Bajaj numbers. They are really bad. Of course, Bajaj has a wonderful export exhibition that takes care and that is why the overall number of bajaj looks even better. But small cars as well as a two-wheeler are a challenge, and we know, there were demand limits and everyone was talking about it. We hope that the festive season will improve after monsoon. We have to wait and see, it’s so much. Since things are standing today, there is a problem up to the demand for small cars as well as two wheelers.
ET now: Why are we talking about pharma, Shera just said that Trump was actually doing everything he promised and he had previously warned the street about at least 200% of tariffs. Do you think it can really turn to the fruit, whatever it can happen on the front, are you looking back home on our pharma sector?
Sudip Bandyapadhyay: Well, one thing is very sure that as long as Mr. Trump is president, instability is the order of the day and we have to race ourselves. Every day there is something new and some new tweets come or some communication, an interview in which the market is disturbed and it is the order of the day. As far as pharma is concerned, there is not a viable proposal for putting a 200% tariff or otherwise and for us and customers who are trying to save Trump. Therefore, he will not venture there. But yesterday and today’s initiative where he was the CEO of the Pharma Company. A letter has been written to reduce prices, it is definitely a threat and some Indian companies who have the U.S. There is a big business in which it will definitely affect. If it takes any other step, some other disciplinary steps or some other steps that it takes to ensure that it complies that communicates, then it is a matter of great concern and concern. Therefore, in these circumstances, and this view I have been maintaining for a while, it is better to take some care about the companies that are in significant contact in the US market and the US. It is better to focus on companies with less or no exposure as long as the markets are concerned. Therefore, we were just talking about mankind pharma, it is a company that has received 95% of sales in India and the results were appropriate. Therefore, one can focus on companies like this who have limited significant domestic attendance and presence of the US.
(Now you can subscribe to our Etmarkets WhatsApp channel)